Case Report

Waldenstrom’s Macroglobulinemia: A Report of Two Cases, One with Severe Retinopathy and One with Renal Failure

Naoko Kudo,1 Masakatsu Usui,2 Yukiharu Nakabo,3 Ken-ichi Yoshida,4 Kenji Miki,2 Takashi Osafune,5 Keisuke Nishimura,6 and Shinsaku Imashuku1

1Division of Hematology, Takasago-seibu Hospital, Takasago 676-0812, Japan
2Department of Internal Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
3The Center for Hematological Diseases, Takeda General Hospital, Kyoto 601-1495, Japan
4Division of Ophthalmology, Takasago-seibu Hospital, Takasago 676-0812, Japan
5Department of Urology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
6Department of Pathology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
7Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan

Correspondence should be addressed to Shinsaku Imashuku; shinim95@mbox.kyoto-inet.or.jp

Received 25 June 2017; Revised 16 September 2017; Accepted 3 October 2017; Published 31 October 2017

Copyright © 2017 Naoko Kudo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report here two cases of Waldenstrom’s macroglobulinemia (WM), one with central nervous system (CNS) symptoms and severe retinopathy and one with renal failure. In both cases, the serum IgM levels exceeded 3,000mg/dL and monoclonal IgM-kappa was observed in the blood. At onset, Case 1, a 63-year-old female, developed CNS symptoms—namely, drowsiness and syncope. Case 2, a 58-year-old male, had nausea and dysgeusia on admission associated with renal failure, which is quite rare in patients with WM. Both patients exhibited hyperviscosity-related retinopathy, but it was particularly severe in Case 1: she suddenly lost her vision after admission. However, her vision recovered completely during treatment. Case 2 required hemodialysis immediately after admission. Needle biopsy of his kidney revealed tubulointerstitial nephritis with marked infiltration with CD20-positive lymphoplasmacytic lymphoma cells. After treatment, Case 1 has been in a remission longer than 8 years, but Case 2 died of pneumonia in 6 months. Since the initial symptoms of WM are ambiguous and vary significantly and hyperviscosity-related ophthalmological problems or severe renal dysfunction can arise, it is essential to promptly measure serum IgM levels and to institute appropriate care immediately when WM is confirmed in a patient.

1. Introduction

Waldenstrom’s macroglobulinemia (WM) is a lymphoplasmacytic lymphoma (LPL) that is characterized by high levels of monoclonal immunoglobulin M (IgM) protein in the blood. WM is one of low-grade B-cell lymphomas [1, 2]. The incidence of LPL in Japan is very rare. In 1998, it was reported that 22 (0.7%) of all 3,194 malignant lymphomas diagnosed in Japan were LPLs. Since the vast majority of LPLs are WM, this indicates that WM is exceedingly uncommon in Japan [3]. A diagnosis of WM is made when the monoclonal IgM-kappa protein that associates with ≥10% clonal LPL cells in the bone marrow is detected [1]; however, this 10% cutoff seems not to be mandatory, because there are a number of patients with <10% bone marrow involvement with high-serum IgM and viscosity levels, necessitating therapy [1, 2]. Also, it is often difficult to diagnose WM morphologically because the lymphoplasmacytoid LPL cells in the bone marrow can resemble mature lymphocytes or plasma cells [4, 5]. In terms of immunophenotype, lymphoplasmacytoid LPL cells generally express CD19, CD20, and kappa light chain. In addition, CD38 and/or CD138 can be used to identify plasmacytoid lymphocytes [6]. Recent studies have shown that there are several genomic abnormalities that are characteristic for WM: the most common are the L265P mutation in MYD88 (found in 95–97% of patients with WM) and a somatic mutation in CXCR4 (found in 30–40% of patients with WM) [7]. These
mutations (MYD88 and CXCR4) were mentioned to have the impact on treatment decisions on WM [8].

The symptoms of WM range from vague general symptoms such as fatigue, weight loss, and anorexia to more specific symptoms—namely, anemia/thrombocytopenia (due to LPL cell infiltration in the bone marrow), hyperviscosity (due to elevated serum levels of a high molecular weight IgM pentamer), and hyperviscosity-related neurological, vascular, and hemorrhagic symptoms. The neurological symptoms include dizziness, ataxia, paresthesia, and coma. The hemorrhagic symptoms include epistaxis, gingival and gastrointestinal hemorrhage, and menorrhagia: these symptoms arise from vascular disturbances [1, 2]. A particularly characteristic finding in WM is retinopathy (specifically, dilated retinal veins, retinal hemorrhage, and papilledema) [9, 10]. In addition, WM occasionally associates with nephropathy (it appears to be much more common in multiple myeloma). Nephropathy can arise via various mechanisms, including the infiltration of the kidneys with LPL cells [11]. Several prognostic risk factors have been identified for WM—namely, an older age, presence of anemia or thrombocytopenia, high levels of serum β2 microglobulin, and high monoclonal IgM concentrations. It is recommended to adjust the treatment for WM according to the presence of these risk factors [1, 2, 8]. In terms of eventual outcome, a number of highly effective therapeutic agents are now available for WM, and the prognosis is not as dire as it once was, but it still remains incurable [1, 12, 13]. We report here two cases of WM; one with CNS symptoms and severe retinopathy, and one with renal failure.

2. Case Report

2.1. Case 1. A 63-year-old Japanese female was referred with complaints of lightheadedness and drowsiness. In the 2 weeks prior to admission, she had episodes of fainting at the shopping mall and in the bathroom at home. When she attended the clinic near her home, she was found to have high levels of serum IgM. On admission in our hospital, she was alert with no disorientation but exhibited slight confusion with nasal and genital hemorrhages. In the first 8 weeks after admission, she developed a sudden loss of vision due to severe retinopathy (Figure 3(a)) in association with nasal hemorrhages. Fortunately, while on the initial treatment, the patient’s vision recovered completely (4 weeks after the patient reported having loss of vision). Her serum IgM levels dropped gradually but constantly in response to the initial treatment and the following monthly rituximab treatment. After 6 months, her serum IgM levels were <500mg/dL, and we started oral thalidomide (100mg/day, daily) combined with rituximab every 4 months as the maintenance treatment. Eight years after the WM diagnosis, the patient has been in remission and the following monthly rituximab treatment. After 6 months, her serum IgM levels were <500mg/dL, and we started oral thalidomide (100mg/day, daily) combined with rituximab every 4 months as the maintenance treatment. Eight years after the WM diagnosis, the patient has been in remission.

| Table 1: Clinical features and laboratory data. |
|-----------------------------------------------|
| **Case 1** | **Case 2** |
| Age (yrs)/gender | 63/F | 58/M |
| Chief complaints | Lightheadedness | Nausea |
| | Drowsiness | Dysgeusia |
| | Blurred vision | Oliguria |
| Major clinical features | Retinopathy (group 3*) | Renal failure (group 3**) |
| Laboratory data on admission | | |
| | WBC (µL) | 6,900 | 8,200 |
| | Hb (g/dL) | 7.9 | 8.2 |
| | Platelet counts (µL) | 124,000 | 107,000 |
| | CRP (mg/dL) | 0.19 | 1.15 |
| | LDH (U/L) | 174 | 102 |
| | Total protein (g/dL) | 9.2 | 9.3 |
| | Albumin (g/dL) | 2.1 | 3.2 |
| | Serum BUN (mg/dL) | 20.9 | 124.4 |
| | Creatinine (mg/dL) | 1.25 | 11.1 |
| | Na (mmol/L) | 135 | 137 |
| | K (mmol/L) | 4.3 | 7.6 |
| | CI (mmol/L) | 98 | 112 |
| | IgG (mg/dL) | 427 | 473 |
| | IgA (mg/dL) | 137 | 20 |
| | IgM (mg/dL) | 6,080 | 3,603 |
| | Beta-2-MG (mg/dL) | 4.0 | 36.5 |
| | sIL-2R (U/L) | 767 | NT |
| | Monoclonal protein | IgM-kappa | IgM-kappa |
| | Proteinuria | 2+ | 2+ |
| | MYD88 | NT | NT |
| **Treatment** | | |
| Initial management and chemotherapy induction | DFPP/PE/rituximab/2-CDA | Hemodialysis/Rituximab/bendamustine |
| Maintenance | Rituximab/thalidomide | None |
| **Outcome** | | |
| Alive (yrs) | 8+ | 0.5*** |

*Defined by Menke et al. [14]; ** defined by Chauvet et al. [21], Vos et al. [11], and Audard et al. [20]; *** died of severe pneumonia after the sixth cycle of rituximab/bendamustine. NT = not tested, MYD88 = myeloid differentiation 88, DFPP = double-filtration plasmapheresis. PE = plasma exchange, 2-CDA = 2-chloro-2’-deoxyadenosine.
remission without any symptoms. She has normal serum IgM levels, a normal free light chain kappa/lambda ratio with residually detectable M protein in her blood.

2.2. Case 2. A 58-year-old Japanese male was transferred to the clinic near his home due to renal failure. Eight months prior to admission, his renal function was normal (serum BUN 14 mg/dL and creatinine 0.87 mg/dL) and he was not anemic (Hb 10.0 g/dL). One month prior to admission, the patient complained of nausea, loss of appetite, decreased water intake, dysgeusia, watery diarrhea, and oliguria. On admission, he was alert and afebrile, with a BP of 118/59 mmHg, a HR of 67 bpm, a SpO₂ of 99% (room air), and a RR of 16/min. His laboratory data are summarized in Table 1. A peripheral blood smear clearly exhibited rouleaux formation (Figure 1(b)). His bone marrow was infiltrated with LPL cells (32% of NCC) that were positive for CD19 and CD38 (original magnification, ×400).

Figure 1: Peripheral blood smears from (a) Case 1 and (b) Case 2, which exhibit rouleaux formation of the red blood cells.

Figure 2: Immunostaining of lymphoplasmacytic lymphoma (LPL) cells in the bone marrow clot preparation from Case 1. The LPL cells were diffusely positive for CD20 but only sporadically positive for CD38 (original magnification, ×400).

Figure 3: Fundoscopic findings. (a) Case 1 exhibited bilateral central retinal vein occlusion (CRVO) and optic nerve head edema with diffuse peripheral and central retinal hemorrhages that were accompanied by a large vitreous hemorrhage. (b) Case 2 exhibited bilateral tortuous blood vessels with a rod-like retinal hemorrhage (left eye) without macular edema.
CD20 (28.3%), and kappa light chain (38.3%). The bone marrow clot section contained aggregates of LPL cells that were positive for CD20 and CD138 (data not shown). The bone marrow karyotype was 46, XY (20/20). Other laboratory data, including the collagen disease markers for systemic lupus erythematosus, were all negative. Although the patient did not complain of vision problems, fundoscopy revealed bilateral tortuous blood vessels with a few hemorrhages but no macular edema (Figure 3(b)). The patient’s main problem was renal failure that was characterized by high serum levels of BUN (124.4 mg/dL), creatinine (11.1 mg/dL), and beta-2-microglobulin (beta-2-MG; 36.5 mg/dL). Given that the renal failure had led to hyperkalemia (7.6 mmol/L), oliguria, and metabolic acidosis (pH 7.110; BE: −17.9 mmol/dL), hemodialysis (three days a week) was introduced immediately. In addition, to clarify the pathogenesis of the renal failure, a needle biopsy of the right kidney was performed on day 12 of admission. Light and electron microscopic studies of the biopsied kidney tissue revealed massive interstitial LPL cell infiltration, while the fluorescence microscopic study revealed mild dot-like mesangial IgM depositions (Figure 4). Given his relatively young age and presumed poor outcome, the patient was sent to a tertiary referral center for renal failure care and chemotherapy. At the referral center, BR chemotherapy, a combination of rituximab (375 mg/m², drip, day 1) and bendamustine (90 mg/m², drip, days 2 and 3) q 4 weeks, was started with continuation of hemodialysis. After 3 courses of a total of 6 courses of BR chemotherapy planned, the patient’s condition was stable with serum creatinine 4.57 mg/dL and IgM 1,246 mg/dL, showing gradual improvement in renal function; however, considering the reduction rate of serum creatinine, it seemed not to be possible for the patient to make a successful hemodialysis withdrawal. Unfortunately, the patient died of severe pneumonia during maintenance dialysis after the sixth cycle of rituximab/bendamustine chemotherapy.

3. Discussion

The clinical features of WM vary from anemia/thrombocytopenia that is due to LPL infiltration in the bone marrow to CNS symptoms that are due to the hyperviscosity, which is caused by the high serum IgM concentrations. In particular, the thickened blood causes poor brain circulation, which leads to CNS problems such as confusion, dizziness, and syncope: these CNS symptoms were all apparent in our Case 1. Another sign of the hyperviscosity that characterizes WM is vision problem such as blurred vision or blindness: this reflects the fact that hyperviscosity impairs the circulation in the retina and causes hemorrhages around the small retinal vessels [9, 10, 14]. In addition, although renal problems are uncommon in WM (∼5%) (unlike in multiple myeloma, where it occurs in 30–40% of patients), nephropathy (namely, nephrotic syndrome, renal failure, and uremic encephalopathy) can arise in patients with WM [11, 15]. Below, we will discuss three issues—namely, WM-related retinopathy, WM-related nephropathy, and the recent progress in the management of WM.

WM-related eye diseases vary from bilateral simultaneous central retinal vein occlusion (CRVO) [9, 10] and
bilateral serous macular detachment [16] to LPL infiltration of the optic nerve [17]. However, vision loss in WM is mostly caused by bilateral simultaneous CRVO that is caused by hyperviscosity: it is estimated to affect 15–17% of all patients with WM [9, 18]. Notably, when Menke et al. studied the funduscopic findings in 46 patients with WM, they were able to classify them into three groups depending on the degree of the retinopathy. Thus, group 1 had no signs of retinopathy (52%), group 2 exhibited dilated retinal veins with peripheral retinal hemorrhages (39%), and group 3 had optic disc edema, peripheral and central retinal hemorrhages, and venous sausaging (9%). Menke et al. found that the mean serum IgM level associated with the first retinal changes in WM was 5,442 mg/dL (range: 2,950–8,440 mg/dL) [14]. Indeed, our Case 1, who developed blindness due to the group 3–type renal damage defined by Menke et al., had IgM levels of 6,080 mg/dL at the time the blindness arose. Moreover, our Case 2 showed mild retinopathy when his serum IgM level was 3,603 mg/dL. These observations suggest that when patients exhibit bilateral simultaneous CRVO and hyperviscosity, their serum IgM levels must be determined. In addition, when a patient with WM is diagnosed, they should undergo routine funduscopic evaluation. It is possible to reverse retinopathy and reduce the abnormal venous dilatation in WM by plasmapheresis [19]. However, it has been noted that even when multiple plasmapheresis treatments are given, serous macular detachments can persist [16]. Nevertheless, in our Case 1, her severe retinopathy was successfully cured by her treatment, which consisted of four courses of plasma exchange, rituximab, and 2-CDA chemotherapy.

Various monoclonal IgM-secreting lymphoproliferative diseases, including WM, are associated with renal lesions [11, 20, 21]. According to Vos et al., the cumulative incidence of renal involvement in WM is 5.1% in 15 years [11]. Recently, Chauvet et al. [21] examined 35 patients with renal damage that related to B-cell lymphoproliferative disease involving monoclonal IgM secretion. Of the 35 patients, 26 had WM. Chauvet et al. were able to divide the 35 patients into three groups on the basis of their renal pathology. Thus, group 1 had glomerular AL amyloidosis (31.4%), group 2 had non-amyloid glomerulopathies (42.8%), and group 3 had tubulointerstitial nephropathies (25.7%: this included three cases of LPL infiltration). The study of Vos et al. on the WM-related nephropathy also showed three major similar groups on the basis of their renal pathology; 25% had group 1–type renal damage (amyloidosis), 23% had group 2–type renal damage (monoclonal IgM deposition disease/cryoglobulinemia), and 18% had group 3–type renal damage (tubulointerstitial LPL infiltration), and the remaining consisted of other types of renal damage [11]. In addition, in an analysis of eight cases of WM nephropathy by Audard et al. [20], three patients had tubulointerstitial LPL infiltration (i.e., group 3–type renal damage; 37.5%). In terms of symptoms, Chauvet et al. [21] reported that nephrotic syndrome was mostly observed in groups 1 and 2, whereas acute kidney injury and/or proximal tubular dysfunction were noted in group 3. In our Case 1, nephropathy did not arise despite the fact that she had proteinuria on admission. In our Case 2, it was difficult to determine whether he had acute renal failure or not. However, the kidney damage did progress quite rapidly: he had normal kidney function only 8 months prior to his admission for renal failure. The main cause of his renal failure was tubulointerstitial LPL infiltration (i.e., he had group 3–type renal damage; Figure 4). However, the impact of the mild mesangial IgM deposition that was observed is unknown. In terms of response to therapy by patients with biopsy-confirmed monoclonal IgM nephropathy, Chauvet et al. [21] reported that five of ten evaluable group 1 patients, nine of fifteen evaluable group 2 patients, and five of eight evaluable group 3 patients exhibited a renal response to first-line treatment. In addition, Vos et al. [11] showed that the median overall survival of WM patients with nephropathy was 11.5 years, which was shorter than the overall survival of the WM patients without nephropathy (16 years, \( P = 0.03 \)). However, the patients with nephropathy whose renal function remained stable or improved after treatment had better overall survival than those whose nephropathy worsened despite treatment (\( P = 0.05 \)). Unfortunately, in our Case 2, the renal damage was progressed prior to the initiation of chemotherapy; thus, it seemed not to be possible for the patient to make a successful hemodialysis withdrawal.

Regarding the management of WM, it was proposed that initiation of therapy can be based on symptoms such as recurrent fever, night sweats, fatigue, anemia, or weight loss rather than on the serum IgM levels. In addition, symptoms due to hyperviscosity syndrome, renal insufficiency, or symptomatic cryoglobulinemia may also be indications for therapy initiation [22]. Besides effective plasmapheresis in the management of hyperviscosity [19], chemotherapy with a combination of rituximab and 2-chloro-2′-deoxyadenosine (2-CDA), or of rituximab and bendamustine, has been proven effective for WM [23–25]. This was confirmed by the success of rituximab/2-CDA combination therapy in our Case 1 as well as a partial response of rituximab/bendamustine therapy in our Case 2. We also successfully managed Case 1 during the maintenance therapy with a combination of rituximab and thalidomide. More recent treatment recommendations in the international consensus paper for WM include other novel and promising agents such as ofatumumab, lenalidomide, bortezomib, and the BTK inhibitor ibrutinib. [8]. However, because of his early death, our Case 2 lost the chance of receiving such novel therapeutic measures.

In summary, we presented two cases of WM; one with CNS symptoms and severe retinopathy, and one with renal failure that was due to tubulointerstitial infiltration of LPL cells (as confirmed by renal biopsy). To obtain excellent outcomes in patients with WM, it is essential that ophthalmological and/or renal problems are early diagnosed and appropriately managed.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Acknowledgments**

The authors thank Drs. Yoshio Akagi and Ken-ichi Kai for their ophthalmological management and Dr. Shin-ichi Kotani for his helpful discussion and advice in Case 2.
References

[1] M. A. Gertz, “Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management,” American Journal of Hematology, vol. 92, no. 2, pp. 209–217, 2017.

[2] J. J. Castillo, R. Garcia-Sanz, E. Hatjiharissi et al., “Recommendations for the diagnosis and initial evaluation of patients with Waldenström macroglobulinaemia: a task force from the 8th International Workshop on Waldenström macroglobulinaemia,” British Journal of Haematology, vol. 175, no. 1, pp. 77–86, 2016.

[3] Lymphoma Study Group of Japanese Pathologists, “The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities,” Pathology International, vol. 50, no. 9, pp. 696–702, 2000.

[4] W. G. Morice, D. Chen, P. J. Kurtin, C. A. Hanson, and E. D. McPhail, “Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinaemia,” Modern Pathology, vol. 22, no. 6, pp. 807–816, 2009.

[5] F. Berger, A. Traverse-Glehen, P. Felman et al., “Clinico-pathologic features of Waldenstrom’s macroglobulinaemia and marginal zone lymphoma: are they distinct or the same entity?,” Clinical Lymphoma, vol. 5, no. 4, pp. 220–224, 2005.

[6] M. C. Kyrtsonis, G. Levidou, P. Korkolopoulou et al., “CD138 expression helps distinguishing Waldenström’s macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL),” Clinical Lymphoma Myeloma Leukemia, vol. 11, no. 1, pp. 99–102, 2011.

[7] Z. R. Hunter, G. Yang, L. Xu, X. Liu, J. J. Castillo, and S. P. Treon, “Genomics, signaling, and treatment of Waldenstrom macroglobulinaemia,” Journal of Clinical Oncology, vol. 35, no. 9, pp. 994–1001, 2017.

[8] V. Leblond, E. Kastritis, R. Advani et al., “Treatment recommendations from the Eighth International Workshop on Waldenström’s macroglobulinaemia,” Blood, vol. 128, no. 10, pp. 1321–1328, 2016.

[9] P. Alexander, D. Flanagan, K. Rege, A. Foss, and M. Hingorani, “Bilateral simultaneous central retinal vein occlusion secondary to hyperviscosity in Waldenström’s macroglobulinaemia,” Eye, vol. 22, no. 8, pp. 1089–1092, 2008.

[10] B. Chanana, N. Gupta, and R. V. Azad, “Case report: bilateral simultaneous central retinal vein occlusion in Waldenström’s macroglobulinaemia,” Optometry, vol. 80, no. 7, pp. 350–353, 2009.

[11] J. M. Vos, J. Gustine, H. G. Rennke et al., “Renal disease related to Waldenström macroglobulinemia: incidence, pathology and clinical outcomes,” British Journal of Haematology, vol. 175, no. 4, pp. 623–630, 2016.

[12] J. J. Castillo, A. J. Olszewski, S. Kanan, K. Meid, Z. R. Hunter, and S. P. Treon, “Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database,” British Journal of Haematology, vol. 169, no. 1, pp. 81–89, 2015.

[13] J. P. Abeykoon, U. Yanamandra, and P. Kapoor, “New developments in the management of Waldenström macroglobulinaemia,” Cancer Management Research, vol. 9, pp. 73–83, 2017.

[14] M. N. Menke, G. T. Feke, J. W. McMeel, A. Branagan, Z. Hunter, and S. P. Treon, “Hyperviscosity-related retinopathy in Waldenström macroglobulinaemia,” Archives of Ophthalmology, vol. 124, no. 11, pp. 1601–1606, 2006.

[15] M. A. Dimopoulos, E. Terpos, A. Chanan-Khan et al., “Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4976–4984, 2010.

[16] A. F. Pilon, P. S. Rhee, and L. V. Messner, “Bilateral, persistent serous macular detachments with Waldenström’s macroglobulinemia,” Optometry and Vision Science, vol. 82, no. 7, pp. 573–578, 2005.

[17] H. Nishida, R. Hashida, M. Hatano, M. Hori, and K. Obara, “Optic nerve involvement of Waldenström’s macroglobulinaemia: with autopsy findings,” Neurological Sciences, vol. 35, no. 8, pp. 1299–1302, 2014.

[18] G. Merlino, L. Baldini, C. Broglia et al., “Prognostic factors in symptomatic Waldenström’s macroglobulinaemia,” Seminars in Oncology, vol. 30, no. 2, pp. 211–215, 2003.

[19] M. N. Menke, G. T. Feke, J. W. McMeel, and S. P. Treon, “Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenström’s macroglobulinaemia,” Investigative Ophthalmology & Visual Science, vol. 49, no. 3, pp. 1157–1160, 2008.

[20] V. Audard, B. Georges, P. Vanhille et al., “Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum,” Clinical Journal of American Society of Nephrology, vol. 3, no. 5, pp. 1339–1349, 2008.

[21] S. Chauvet, F. Bridoux, L. Ecotière et al., “Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients,” American Journal of Kidney Diseases, vol. 66, no. 5, pp. 756–767, 2015.

[22] R. A. Kyle, S. P. Treon, R. Alexanian et al., “Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinaemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinaemia,” Seminars in Oncology, vol. 30, no. 2, pp. 116–120, 2003.

[23] M. A. Dimopoulos, E. Kastritis, M. Roussou et al., “Rituximab-based treatments in Waldenström’s macroglobulinaemia,” Seminars in Oncology, vol. 9, no. 1, pp. 59–61, 2009.

[24] D. Laszlo, G. Andreola, L. Rigacci et al., “Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenström macroglobulinaemia: clinical and biologic results of a phase II multicenter study,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2233–2238, 2010.

[25] M. Varettoni, E. Marchioni, M. Bonfichi et al., “Successful treatment with rituximab and bendamustine in a patient with newly diagnosed Waldenström’s macroglobulinaemia complicated by Bing-Neel syndrome,” American Journal of Hematology, vol. 90, no. 8, pp. E152–E153, 2015.
